425: ACELYRIN and Alumis Announce All-Stock Merger to Create Immunology-Focused Biopharma Leader

ACELYRIN and Alumis have agreed to an all-stock merger, creating a late-stage clinical biopharmaceutical company focused on immune-mediated diseases with a combined cash runway extending into 2027.

Summary

• ACELYRIN, Inc. and Alumis Inc. have entered into a definitive merger agreement where Alumis will acquire ACELYRIN in an all-stock transaction.
• ACELYRIN stockholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock.
• Post-merger, Alumis stockholders are expected to own approximately 55% and ACELYRIN stockholders approximately 45% of the combined company on a fully diluted basis.
• The combined company will operate under the name Alumis and will be led by the current Alumis executive team.
• The merger is expected to close in the second quarter of 2025, subject to stockholder approvals and customary closing conditions.
• The pro forma cash position of the combined company is estimated to be around $737 million as of the end of Q4 2024, providing a cash runway into 2027.
• The ACELYRIN board believes the transaction provides potential for substantial value accretion, with intrinsic value per share representing upside to ACELYRIN's current trading price.
• Guggenheim Securities performed financial analyses, including discounted cash flow analyses, to advise the ACELYRIN board on the merger.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook on the merger, highlighting the potential for value creation and a strengthened financial position. However, it also acknowledges various risks and uncertainties associated with the transaction, leading to a moderately positive sentiment score.

Positives

• The merger creates a leading late-stage clinical biopharma company focused on immune-mediated diseases.
• The combined company will have a differentiated and late-stage portfolio targeting large, well-established multi-billion dollar markets.
• The merger provides multiple, meaningful near-term catalysts for the combined company.
• The combined company will be led by a deep and experienced team.
• The pro forma cash position of $737 million provides a cash runway into 2027 to advance the combined pipeline.
• The transaction offers the potential for substantial value accretion for the combined company.

Negatives

• The merger is subject to stockholder approvals and customary closing conditions, which could delay or prevent the transaction from closing.
• The announcement, pendency, or completion of the merger could affect Alumis' or ACELYRIN's ability to attract, motivate, retain, and hire key personnel.
• The merger may divert management's attention from ongoing business operations.
• There is a risk that the anticipated benefits and synergies of the merger may not be fully realized or may take longer to realize than expected.
• The value of Alumis securities to be issued in the merger is subject to risks.
• Integrating ACELYRIN's operations and personnel may not occur as anticipated.

Risks

• The proposed merger may not be completed in a timely manner or at all.
• Required approvals for the merger, including stockholder approvals, may not be received.
• The announcement, pendency, or completion of the merger may negatively impact the ability to retain key personnel and maintain relationships with partners and suppliers.
• The merger may divert management's attention from ongoing business operations.
• Legal proceedings related to the merger could result in expense or delay.
• Economic, business, and/or competitive factors may adversely affect Alumis or ACELYRIN.
• Restrictions during the pendency of the merger may impact the ability to pursue certain business opportunities or strategic transactions.
• The anticipated benefits and synergies of the merger may not be fully realized or may take longer to realize than expected.
• Legislative, regulatory, economic, competitive, and technological changes could impact the combined company.
• The value of Alumis securities to be issued in the merger is subject to risks.
• Integration of the merger post-closing may not occur as anticipated.
• The market price of the common stock of each of Alumis and ACELYRIN may be affected by the announcement, pendency, or completion of the merger.
• There are challenges inherent in developing, commercializing, manufacturing, launching, marketing, and selling potential existing and new products and product candidates.
• Uncertainties exist in contractual relationships, including collaborations, partnerships, licensing, or other arrangements.
• The ability to establish and maintain intellectual property protection for products or avoid or defend claims of infringement is uncertain.
• Potential delays may occur in initiating, enrolling, or completing preclinical studies and clinical trials.

Future Outlook

The combined company expects its pro forma financial plans to extend its cash runway into 2027, and anticipates substantial value accretion.

Industry Context

The merger aims to create a leading late-stage clinical biopharma company in the immune-mediated diseases space, which is a large and competitive market.

Comparison to Industry Standards

• The document references Guggenheim Securities' financial analyses, which include discounted cash flow analyses using discount rates of 13.25% to 15.25% for ACELYRIN on a standalone basis and 12.00% to 14.00% for the pro forma combined company, reflecting their weighted average cost of capital estimates.
• These discount rates are within the typical range used for biopharmaceutical companies, reflecting the inherent risks and uncertainties associated with drug development and commercialization.
• The document does not provide specific comparisons to other comparable companies or projects in terms of financial metrics or clinical trial results.

Stakeholder Impact

• ACELYRIN stockholders will receive shares in the combined company, Alumis.
• Employees of both companies face potential integration and restructuring impacts.
• The combined company aims to develop and commercialize new therapies, potentially benefiting patients.
• Partners and suppliers may experience changes in their relationships with the merged entity.
• Creditors will be impacted by the financial strength and stability of the combined company.

Next Steps

• Alumis intends to file a registration statement on Form S-4 with the SEC, including a joint proxy statement/prospectus.
• Stockholder votes from both Alumis and ACELYRIN will be required to approve the merger.
• The parties will work to satisfy customary closing conditions to complete the merger in the second quarter of 2025.

Key Dates